Limfjords Bio ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  14.4% 7.8% 8.7% 7.9% 8.4%  
Credit score (0-100)  16 31 27 30 23  
Credit rating  B B B B B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  1,052 405 87.1 137 665  
EBITDA  1,052 405 87.1 137 665  
EBIT  1,052 405 87.1 137 665  
Pre-tax profit (PTP)  1,051.7 385.1 12.0 92.4 591.1  
Net earnings  818.0 300.4 9.1 72.1 460.9  
Pre-tax profit without non-rec. items  1,052 385 12.0 92.4 591  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  868 350 59.1 131 592  
Interest-bearing liabilities  0.0 4,828 4,489 10,195 2,955  
Balance sheet total (assets)  1,414 5,571 4,738 10,758 3,687  

Net Debt  -28.5 4,828 4,489 10,195 2,955  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,052 405 87.1 137 665  
Gross profit growth  0.0% -61.5% -78.5% 57.2% 385.6%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,414 5,571 4,738 10,758 3,687  
Balance sheet change%  0.0% 294.0% -15.0% 127.0% -65.7%  
Added value  1,051.7 405.2 87.1 136.9 664.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  74.4% 12.1% 2.3% 2.4% 9.2%  
ROI %  121.2% 14.0% 2.5% 2.5% 9.6%  
ROE %  94.2% 49.3% 4.4% 75.8% 127.5%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  61.4% 6.3% 1.2% 1.2% 16.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -2.7% 1,191.5% 5,154.1% 7,448.8% 444.6%  
Gearing %  0.0% 1,378.0% 7,601.6% 7,775.9% 499.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 1.6% 2.3% 1.2% 1.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  2.6 0.8 0.8 0.6 0.8  
Current Ratio  2.6 1.1 1.0 1.0 1.2  
Cash and cash equivalent  28.5 0.0 0.0 0.0 0.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  868.0 350.4 59.1 131.1 592.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0